HepaStem (LIFELIVER)

N/A

Report date: 2025/08/31 20:00:06

Base Information

Drug NameHepaStem (LIFELIVER)
Drug Alias NameMesenchymal stem cell therapy (HepaStem) - Promethera BiosciencesHuman Adult Liver-Derived Mesenchymal Progenitor/Stem Cells - PrometheraHeterologous Human Adult Liver derived Progenitor CellsHeterologous human adult liver-derived mesenchymal progenitor stem cells (intravenous, acute-on-chronic liver failure/NASH/liver fibrosis/hemophilia A/B), Promethera BiosciencesHHALPC +[8] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Liver-derivedCell and gene therapy > Cell therapy > Somatic cell > Liver progenitor cellsCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionPhenylalanine hydroxylase agonists
TargetsPhenylalanine hydroxylase
Therapy Area/IndicationsUrea Cycle Disorders, InbornAcute-On-Chronic Liver FailureMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaSlovakia +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPromethera Biosciences Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellaion SAHlb Cell Co Ltd
Active IndicationsN/A
Inactive IndicationsUrea Cycle Disorders, InbornAcute-On-Chronic Liver FailureMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A